FDA biological comparability policy may spur generic biologic industry growth -- Fenwick & West's Mackler.
FDA COMPARABILITY POLICY MAY FACILITATE GENERIC BIOLOGICS, Bruce Mackler, PhD, a partner in the Washington, D.C. law firm Fenwick & West, suggested at the Jan. 7 BioEast meeting in Washington, D.C. Under FDA comparability guidelines that allow analytical testing and other assays to substitute for clinical trials, biotech "companies are now encouraged to incorporate new technology very rapidly into the manufacturing process to increase productivity [and] reduce costs," Mackler said. The next step, he said, "is the concept of equivalent biologics, or comparable biologics as generics."
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth